| DrugRepV_3611 | C-c3 Ado | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3612 | 5 Noraristeromycin | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3613 | DHCaA | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3614 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3615 | EICAR | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3616 | Pyrazofurin | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3617 | Carbodine | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3618 | 6-Azauridine | NA | Cancer | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3619 | Poly(I)-poly(C12U) | NA | NA | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3620 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3621 | 6-Azauridine | NA | Cancer | Nipah virus | NA | NA | RT-PCR | Decrease | NA | 16641448 |
| DrugRepV_3622 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Nipah virus | NA | NA | RT-PCR | Decrease | Approved | 16641448 |
| DrugRepV_3671 | 2,6-bis[(3-tert-butyl-2-hydroxy-5-methylphenyl)methyl]-4-methylphenol | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (100 %) | NA | 22027648 |
| DrugRepV_3672 | NSC 62914 | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease | NA | 22027648 |
| DrugRepV_3673 | NSC 62914 | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 22027648 |
| DrugRepV_3674 | Trolox | NA | NA | Ebola virus | Zaire | NA | RT-PCR | Decrease (45 %) | NA | 22027648 |
| DrugRepV_3675 | Trolox | NA | NA | Marburg virus | NA | NA | RT-PCR | Decrease (70 %) | NA | 22027648 |
| DrugRepV_3676 | NSC 62914 | NA | NA | Marburg virus | Ci67 | NA | RT-PCR | Decrease (98 %) | NA | 22027648 |
| DrugRepV_3677 | NSC 62914 | NA | NA | Lassa virus | Josiah | NA | RT-PCR | Decrease (98 %) | NA | 22027648 |
| DrugRepV_3678 | NSC 62914 | NA | NA | Rift Valley fever virus | MP12 | NA | RT-PCR | Decrease (97 %) | NA | 22027648 |
| DrugRepV_3686 | BCX4430 | NA | Ebola virus | Marburg virus | Musoke | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3687 | BCX4430 | NA | Ebola virus | Marburg virus | Ci67 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3688 | BCX4430 | NA | Ebola virus | Marburg virus | Angola | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3689 | BCX4430 | NA | Ebola virus | Ebola virus | Kikwit | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3690 | BCX4430 | NA | Ebola virus | Chikungunya virus | AF 15561 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3691 | BCX4430 | NA | Ebola virus | Rift Valley fever virus | ZH5018 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3692 | BCX4430 | NA | Ebola virus | Lassa virus | Josiah | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3693 | BCX4430 | NA | Ebola virus | Nipah virus | Malaysia | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3694 | BCX4430 | NA | Ebola virus | Middle East respiratory syndrome coronavirus | Jordan N3 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3695 | BCX4430 | NA | Ebola virus | Severe acute respiratory syndrome coronavirus | Urbani | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3696 | BCX4430 | NA | Ebola virus | Influenza virus | pH1N1 |  | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3711 | C795-0925 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3712 | D011-2120 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3713 | F694-1532 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3714 | G202-0362 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3715 | C795-0925 | NA | NA | Ebola virus | Zaire | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3716 | D011-2120 | NA | NA | Ebola virus | Zaire | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3717 | F694-1532 | NA | NA | Ebola virus | Zaire | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3718 | G202-0362 | NA | NA | Ebola virus | Zaire | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3719 | C795-0925 | NA | NA | Marburg virus | Ci67 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3720 | D011-2120 | NA | NA | Marburg virus | Ci67 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3721 | F694-1532 | NA | NA | Marburg virus | Ci67 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3722 | G202-0362 | NA | NA | Marburg virus | Ci67 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3723 | C795-0925 | NA | NA | Lassa virus | Josiah | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3724 | D011-2120 | NA | NA | Lassa virus | Josiah | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3725 | F694-1532 | NA | NA | Lassa virus | Josiah | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3738 | Falnidamol dihydrochloride | NA | Solid Tumor | Lassa virus | NA | NA | RT-PCR | Decrease (50 %) | Investigational | 25986249 |
| DrugRepV_3739 | Falnidamol dihydrochloride | NA | Solid Tumor | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Investigational | 25986249 |
| DrugRepV_3740 | Falnidamol dihydrochloride | NA | Solid Tumor | Marburg virus | NA | NA | RT-PCR | Decrease (50 %) | Investigational | 25986249 |
| DrugRepV_3741 | OSU-03012 | Anticancer | Brain cancer | Lassa virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3742 | Falnidamol | NA | Solid Tumor | Lassa virus | NA | NA | RT-PCR | Decrease (50 %) | Investigational | 25986249 |
| DrugRepV_3743 | OSU-03012 | Anticancer | Brain cancer | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3744 | Falnidamol | NA | Solid Tumor | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Investigational | 25986249 |
| DrugRepV_3860 | Favipiravir | Antiviral | Influenza virus | Marburg virus | Leiden | NA | RT-PCR | Decrease (50 %) | Investigational | 27736754 |
| DrugRepV_5345 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5346 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5347 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5348 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5349 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5350 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5351 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5352 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 21616094 |
| DrugRepV_5353 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5354 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5355 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5356 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5357 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5358 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5359 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5360 | 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide | NA | NA | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | NA | 21616094 |
| DrugRepV_5361 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5362 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5363 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5364 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5365 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5366 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5367 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5368 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5369 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5370 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5371 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5372 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5373 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5374 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5375 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5376 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_6105 | BCX4430 | NA | Ebola virus | Dengue virus | New Guinea C | | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_6107 | Coumarin A | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (50 %) | NA | 28100218 |
| DrugRepV_6108 | Coumarin B | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (50 %) | NA | 28100218 |
| DrugRepV_6109 | Lupeol Acetate 26SK001 | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (50 %) | NA | 28100218 |
| DrugRepV_6110 | Voacangine 26SK002 | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (50 %) | NA | 28100218 |
| DrugRepV_6111 | Coumarin A | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (37.1 %) | NA | 28100218 |
| DrugRepV_6112 | Coumarin B | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (99.25 %) | NA | 28100218 |
| DrugRepV_6113 | Lupeol Acetate 26SK001 | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (23 %) | NA | 28100218 |
| DrugRepV_6114 | Voacangine 26SK002 | NA | NA | Dengue virus | NG | | RT-PCR | Decrease (23 %) | NA | 28100218 |
| DrugRepV_6265 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6266 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6267 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6268 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6269 | Mannan | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6275 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6276 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6277 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6278 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6279 | Mannan | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6400 | HHA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6401 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6402 | HHA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6403 | HHA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6404 | HHA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6405 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6406 | HHA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6407 | HHA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6408 | GNA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6409 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6410 | GNA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6411 | GNA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6412 | GNA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6413 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6414 | GNA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6415 | GNA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6416 | UDA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6417 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6418 | UDA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6419 | UDA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6420 | UDA | NA | NA | Dengue virus | D1/H/IMTSSA/98/606 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6421 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6422 | UDA | NA | NA | Dengue virus | H87 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6423 | UDA | NA | NA | Dengue virus | Dak HD 34 460 | | RT-PCR | Decrease (50 %) | NA | 21738755 |
| DrugRepV_6980 | Octadecyloxyethyl benzyl 9-[(2-phosphonomethoxy)ethyl]guanine | NA | NA | Human immunodeficiency virus | NA | | RT-PCR | Decrease (50 %) | NA | 27933957 |
| DrugRepV_7238 | BCX4430 | NA | Ebola virus | Measles virus | Chicago | | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_7239 | BCX4430 | NA | Ebola virus | Yellow fever virus | 17D | | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_7240 | BCX4430 | NA | Ebola virus | Japanese encephalitis virus | SA14 | | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_7395 | Delphinidin Chloride | NA | NA | West Nile virus | NY-99 | | RT-PCR | Decrease (0.7 Copies/cell) | NA | 28744282 |
| DrugRepV_7396 | Epigallocatechin Gallate | Cardiovascular agents | Hypertension and Diabetic Nephropathy | West Nile virus | NY-99 | | RT-PCR | Decrease (0.7 Copies/cell) | Investigational | 28744282 |
| DrugRepV_7534 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32150618 |
| DrugRepV_7535 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32150618 |
| DrugRepV_7543 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7544 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7550 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7551 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7554 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7555 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7560 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Brazil/RJ-314/2020 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7561 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Brazil/RJ-314/2020 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7562 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7563 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7568 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7569 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7570 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7573 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7574 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7575 | Merimepodib | NA | NA | SARS Coronavirus-2 | SARS-CoV-2 USA-WA1/2020 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7576 | Merimepodib | NA | NA | SARS Coronavirus-2 | SARS-CoV-2 USA-WA1/2020 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7577 | Opipramol | Nervous System | Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7578 | Opipramol | Nervous System | Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7584 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | SARS Coronavirus-2 | Australia/VIC01/2020 isolate) | NA | RT-PCR | Decrease (50 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7585 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | SARS Coronavirus-2 | Australia/VIC01/2020 isolate) | NA | RT-PCR | Decrease (90 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7602 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7603 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7620 | Umifenovir | Antiinfectives For Systemic Use | Prophylaxis/treatment of influenza in Russia and China | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7621 | Umifenovir | Antiinfectives For Systemic Use | Prophylaxis/treatment of influenza in Russia and China | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7627 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7628 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7629 | Saquinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7630 | Saquinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7631 | Oxprenolol | Cardiovascular System | Hypertension, angina pectoris, arrhythmias, and anxiety. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7632 | Oxprenolol | Cardiovascular System | Hypertension, angina pectoris, arrhythmias, and anxiety. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7633 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7634 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7635 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7636 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7643 | Tipranavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7644 | Tipranavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7645 | Dolutegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7646 | Dolutegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7651 | Sulfadoxine | Antiparasitic | Malaria | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7652 | Amprenavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7653 | Amprenavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7657 | Darunavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7658 | Darunavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7661 | Indinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7662 | Indinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |